Record Q1 FY2027 sales rose 8.8% YoY, led by strong growth in EP/Ablation, Neurovascular, and GI segments, while operating profit declined due to higher R&D and personnel costs. Guidance remains unchanged, and a commemorative dividend was announced alongside plans for HQ relocation and a company na…
Record Q1 FY2027 sales rose 8.8% YoY, led by strong growth in EP/Ablation, Neurovascular, and GI segments, while operating profit declined due to higher R&D and personnel costs. Guidance remains unchanged, and a commemorative dividend was announced alongside plans for HQ relocation and a company name change.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
